Treatment of toxic epidermal necrolyis. Experience with 9 patients with consideration of intravenous immunoglobulin;Behandlung der toxischen epidermalen nekrolyse. Erfahrungen bei 9 patienten unter berücksichtigung von intravenösen immunglobulinen

Hautarzt

Volumn 57, Issue 3, 2006, Pages 185-194

  Spornraft Ragaller, P ^a   Theilen, H ^a   Gottschlich, G ^a   Ragaller, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Corticosteroids; Drug reaction Intravenous immunoglobulins; Mortality rate; Toxic epidermal necrolysis

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DICLOFENAC; IMMUNOGLOBULIN; LOCAL ANESTHETIC AGENT; NITRAZEPAM; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISOLONE; TETRAZEPAM; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; CLINICAL ARTICLE; HUMAN; IMMUNOMODULATION; INTENSIVE CARE; PLASMAPHERESIS; PROGNOSIS; REVIEW; SCORING SYSTEM; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADULT; AGED; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; INCIDENCE; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; MALE; MIDDLE AGED; PATIENT CARE TEAM; PREDNISOLONE; SURVIVAL RATE;

EID: 33644990880     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1104-0     Document Type: Review

References (33)

1. Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139(1):33-36
2. Bastuji-Garin S, Fouchard N, Bertocchi M et al. (2000) SCORTEN: a severity -of illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149-153
3. Bastuji-Garin S, Rzany B, Stern RS et al. (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens Johnson Syndrome and erythema multiforme. Arch Dermatol 129:92-96
4. Brown KM, Silver GM, Halerz M et al. (2004) Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 25(1):81-88
5. Campione E, Marulli GC, Carrozzo AM et al. (2003) High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 83(6):430-432
6. Chung WH, Hung SI, Hong HS et al. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982):486
7. Correia O, Delgado L, Ramos JP et al. (1993) Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence CD8 lymphocyte invovement. Arch Dermatol 129:466-468
8. Garcia-Doval I, LeCleach L, Bocquet H et al. (2000) Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 136:323-411
9. Ghislain PD, Roujeau JC (2002) Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 8(1):5
10. Guibal F, Bastuji-Garin S, Chosidow O et al. (1995) Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 131:669-672
11. Halebian PH, Madden MR, Finklestein J et al. (1986) Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 204:503-512
12. Jäckel R, Fuchs M, Raff T, Wiedemann B (2002) Arzneimittelbedingte toxisch epidermale Nekrolyse mit Beteiligung des Intestinal- und Respirationstraktes. Anaesthesist 51:815-819
13. Le Gall R, Lemenshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North american multicenter study. JAMA 270:2957-2963
14. Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68:355-361
15. Magina S, Lisboa C, Leal V et al. (2003) Dermatological and opthalmological sequels in toxic epidermal necrolysis. Dermatology 207(1):33-36
16. McGee T, Munster A (1998) Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 102:1018-1022
17. Mockenhaupt M, Norgauer J (2002) Cutaneous adverse drug reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis. ACI International 14/4:143-150
18. Palmieri TL, Greenhalgh DG, Saffle JR et al. (2002) A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 23(2):87-96
19. Paquet P, Pierard GE, Quatresooz P (2005) Novel treatments for drug-induced toxic epidermal necrolysis (Lyell,s syndrome). Int Arch Allergy Appl Immunol 136(3):205-216
20. Prins C, Kerdel FA, Padilla RS et al. (2003) Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139(1):26-32
21. Reinhart K et al. (2005) S2-Leitlinien der Deutschen Sepsis-Gesellschaft e.V. und der DIVI. Diagnose und Therapie der Sepsis. http://www.awmf-online. de. Ref Type: Electronic Citation
22. Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS (1999) Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 79(4):288-290
23. Roujeau JC, Albengres E, Moritz S et al. (1985) Lymphocyte transformation test in drug- induced toxic epidermal nekrolysis. Int Arch Allergy Appl Immunol 78(1):22-24
24. Roujeau JC, Chosidow O, Saiag P, Guillaume JC (1990) Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 23(6):1039-1058
25. Roujeau JC, Kelly JP, Naldi L et al. (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal nekrolysis. N Engl J Med 333:1600-1607
26. Rzany B, Hering O, Mockenhaupt M et al. (1996) Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 135:6-11
27. Rzany B, Mockenhaupt M, Baur S et al. (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal nekrolysis in Germany (1990-1992): structure and results of a population based registry. J Clin Epidemiol 49(7):769-773
28. Schöpf E, Rzany B, Mockenhaupt M (1995) Schwere arzneimittelinduzierte Hautreaktionen: Pemphigus vulgaris, Bullöses Pephigoid, generalized bulous fixed drug eruption, Erythema exsudativum multiforme majus, Stevens Johnson Syndrom und Toxisch epidermale Nekrolyse. In: Plewig G, Korting HC (Hrsg) Fortschritte der praktischen Dermatologie und Venerologie. Springer, Berlin Heidelberg New York Tokyo, S 89-95
29. Shortt R, Gomez M, Mittmann N, Cartotto R (2004) Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 25(3):246-255
30. Stella M, Cassano P, Bollero D et al. (2001) Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 203:45-49
31. Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2006) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami experience. Arch Dermatol 139(1):39-43
32. Viard I, Wehrli P, Bullani R et al. (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobuline. Science 282:490-493
33. Wolkenstein P, Chosidow O, Flechet ML et al. (1996) Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal nekrolysis. Contact Dermatitis 35(4):234-236